Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...

Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

In a report released today, Gena Wang from Barclays maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price target ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...